Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 126 to 150 of 1146 KECs

ID	Action	Object	Associated Key Events (KEs)


329	increased	Amputation, Congenital (MESH:C565682)	591: Increased, amputations
345	increased	anesthesia (MESH:D000758)	634: N/A, sedation
346	decreased	prostaglandin F2alpha (CHEBI:15553)	2 Events 671: Reduced, Prostaglandin F2alpha concentration, plasma 1104: Decreased, Prostaglandin F2alpha concentration, plasma
348	abnormal	fertility (MESH:D005298)	673: Reduced, Spawning behavior
352	increased	3',5'-cyclic AMP(1-) (CHEBI:58165)	693: Increased, cyclic adenosine monophosphate
353	decreased	Gonadotropin Releasing Hormone (MESH:D007987)	689: Reduced, Gonadotropin releasing hormone, hypothalamus
354	decreased	steroid hormone (CHEBI:26764)	691: Reduced, Maturation inducing steroid, plasma
366	increased	Adenoma (MESH:D000236)	9 Events 713: Increase, Adenomas/carcinomas (renal tubular) 719: Increase, hepatocellular adenomas and carcinomas 736: Increase, Adenomas/carcinomas (bronchioloalveolar) 741: Increase, Adenomas/carcinomas (follicular cell) 773: Increase, Endometrial adenocarcinomas 797: Increase, Adenomas/carcinomas (urothelial) 1026: Increased Apoptosis, Adenomas/carcinomas (follicular cell) 1053: Promotion, ovarian adenomas 1079: Increased, Adenomas/carcinomas (mammary)
367	increased	Carcinoma (MESH:D002277)	10 Events 713: Increase, Adenomas/carcinomas (renal tubular) 719: Increase, hepatocellular adenomas and carcinomas 736: Increase, Adenomas/carcinomas (bronchioloalveolar) 741: Increase, Adenomas/carcinomas (follicular cell) 773: Increase, Endometrial adenocarcinomas 779: Increase, Papillomas/carcinomas (squamous cells) 797: Increase, Adenomas/carcinomas (urothelial) 1026: Increased Apoptosis, Adenomas/carcinomas (follicular cell) 1063: Increased, Pancreatic acinar tumors 1079: Increased, Adenomas/carcinomas (mammary)
369	increased	major urinary protein (rat) (PR:P02761)	708: Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
388	increased	Thyroid stimulating hormone (CHEBI:81567)	2 Events 753: Increase, Thyroid-stimulating hormone (TSH) 1023: Increased, Thyroid-stimulating hormone (TSH)
392	increased	Luteinizing hormone (CHEBI:81568)	2 Events 754: Increased, Luteinizing hormone (LH) 791: Increased, Leutinizing hormone (LH)
393	decreased	Prolactin (CHEBI:81580)	747: Decreased, Prolactin
398	decreased	population quality (PCO:0000003)	765: Decreased, population 1
404	increased	papilloma (MESH:D010212)	779: Increase, Papillomas/carcinomas (squamous cells)
405	increased	tyrosine (CHEBI:18186)	775: Increased, Plasma tyrosine
428	decreased	mevalonate (CHEBI:25350)	805: Decreased, mevalonate
429	decreased	cholesterol (CHEBI:16113)	None
431	morphological change	male reproductive system (UBERON:0000079)	809: malformed, Male reproductive tract
440	increased	creatinine (CHEBI:16737)	813: Increased, Serum creatinine
446	functional change	Lipid bilayer of wall of lysosome (FMA:67514)	829: Damage, Lipid bilayer
451	functional change	lysosome (GO:0005764)	831: Disturbance, Lysosomal function
452	increased	porphyrins (CHEBI:26214)	846: Accumulation, Highly carboxylated porphyrins
457	increased	uroporphyrinogen (CHEBI:27258)	844: Oxidation, Uroporphyrinogen
462	increased	Metaplasia (MESH:D008679)	869: Increase, Respiratory or Squamous Metaplasia